ArticleiScience2026
Photoacoustic imaging-guided, synchronously targeted thrombolysis and neuroprotection of acute ischemic stroke.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogen Sulfide Protects Against Cerebral Ischemia-Reperfusion Injury in Rats via S-Sulfhydrating NAMPT to Enhance Mitochondrial Function and Autophagy in Cerebrovascular Endothelial Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Adjuvant neuroprotective therapies for acute ischemic stroke in the reperfusion era: a comparative narrative review of clinical evidence for edaravone, edaravone-dexborneol, and butylphthalide.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke (AIS) is a major cause of disability and mortality worldwide, typically resulting from a thrombus that blocks cerebral blood flow. Current treatments focus on thrombolysis and neuroprotection, with recombinant tissue plasminogen activator (rt-PA) and edaravone (Eda) as key drugs. However, their therapeutic efficacy is constrained by poor targeting, leading to suboptimal drug delivery to the brain. Herein, we develop a biomimetic delivery system (PLEA, platelet membrane-liposome hybrid delivery system encapsulating Eda and rt-PA) by hybridizing platelet membranes with liposomes, leveraging natural thrombus-targeting ability of the platelet membrane to enhance drug delivery efficiency. PLEA effectively targeted thrombus sites, synchronously enhancing thrombolysis and providing neuroprotection in a mouse model of AIS. Photoacoustic (PA) imaging was used to monitor clot formation and assess changes in intracranial blood flow and oxygen levels. These findings indicate that PA imaging-guided PLEA treatment represents a promising approach for precise stroke treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.